Skip to contentI
Inovio Pharmaceuticals, Inc.
I
INOInovio Pharmaceuticals, Inc. Q2 2021 · 10-Q
Revenue$272.82K$272.82K+2.1% vs Q2 2020 Net Income-$82.14M-$82.14MN/M vs Q2 2020 EPS Diluted-$0.39-$0.39N/M vs Q2 2020 Operating Income-$83,201,935N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Inovio Pharmaceuticals, Inc. · CIK 1055726 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$78,667,141N/M Margins · derivedOperating margin-30496.6%−18078.0 pt vs Q2 2020
Net margin-30107.3%+18062.3 pt vs Q2 2020
ended Jun 30, 2021 · filed Aug 9, 2021 · 40 d after period end